ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. - Wikidata - awgldk - TriplyDB

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

http://www.wikidata.org/entity/Q34153957

about

Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma Stem cells of ependymoma Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons New chemotherapy strategies and biological agents in the treatment of childhood ependymoma Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 The Similarities and Differences between Intracranial and Spinal Ependymomas : A Review from a Genetic Research Perspective The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors Cell death or survival promoted by alternative isoforms of ErbB4 Molecular genetics of ependymoma Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.A prognostic gene expression signature in infratentorial ependymoma.Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis Biologically targeted therapeutics in pediatric brain tumors.Biology and management of ependymomas.System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.Molecular neuropathology of gliomas.Brain cancer propagating cells: biology, genetics and targeted therapies Spinal cord ependymoma: a review of the literature and case series of ten patients.Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

P2860

Q24646111-355214CB-E94E-47B1-A8AC-C1114894F56C Q24653517-703C2769-1F38-452A-A5E4-E24BC956A097 Q24654644-63D4A7C5-A715-4C57-8EDF-9F506C5BC611 Q24658324-02F2526C-9D1D-47C7-A950-19FCE76C149F Q24658389-705DBE56-9F7B-492A-BC8D-C6432B090A0B Q24683906-ADAF1D0D-7561-4099-B221-25B91033F201 Q26766642-F5B3E7B4-7E91-4258-9D32-06B3618A78D8 Q28070264-5E7770D3-C431-4FEE-B91B-85600040EA86 Q28593348-1B54426B-129D-4FDE-A404-515EBB30B4F3 Q30438459-D36C4BA8-C2FD-4C05-A480-57ACFA61A62F Q30613404-F7FD4D02-8840-4E79-A15B-134F6F3BEF35 Q33581494-B6EE4BC9-FCEB-4757-8AAB-5EB9350B817C Q33591646-253DBCE1-976A-436D-8821-23E8621EDCC2 Q34132926-29E18456-D4A9-4F43-9D77-C62153311ED6 Q34132933-C72581A0-17FA-428B-920F-68847A844BFF Q34193975-66879CB4-2FD0-4EF9-BF49-03997AFF7976 Q34480582-68AE1A16-EED3-4404-B341-4A2306A13FD9 Q34582560-1AD90960-59AD-4A3A-ABEF-EC3FF983AE0F Q34958888-C7491225-AB26-4F63-9E66-33FEB42B73DA Q35053098-19E3E293-2966-4DDF-A6F7-DCF9BFCB136C Q35085321-61C4F266-16DA-447E-B30F-14C9BCD71181 Q35146683-5B885F0A-270E-43FE-9760-9E6099960B7B Q35212577-5143B2EA-A36D-4C55-8A0E-985F6B764428 Q35229738-D694C871-0236-4DDD-AC2D-E7033341B369 Q35583984-22E32E27-2BB4-4E98-B976-9FB1FCEB5CE6 Q36344765-77C7334B-8F0C-4DA9-BA80-B10939C0E0B3 Q36844744-627BEA81-3C65-4E92-AA3A-58BDEFFE2A69 Q36977704-ADD3DB8D-20E6-4C45-89E1-B57D126EDB42 Q37021760-98CA0A27-4A25-48C4-848F-630EAD1792A7 Q37193464-A16F04F1-49CF-4DA8-989C-AD470C820AAB Q37213305-3F750160-2BF6-4BD1-B49D-F3030E809CE6 Q37316174-8C80A20C-74E4-4CAB-B827-48BC8B54F1ED Q37427424-59BB1A96-9F5D-479C-880E-9EBAB61B8F38 Q37627436-94390FFC-50D6-43A5-8034-F8C9B84EDBFE Q38827823-14D823FE-16B9-4862-AA69-9F7C73FE4356 Q39451532-0BD71266-3AD8-48A0-BE1A-E85D7800CBE9 Q40357721-6E1D006D-2F1C-463E-A8ED-8F324D8E2F5D Q41109977-4FAF06D3-CB40-4702-B25F-6E6080AE2FEA Q47591626-67539B81-33E5-442F-9769-EF3350F4A742

P2860

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

http://www.wikidata.org/entity/Q34153957

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

ERBB receptor signaling promot ...... eutic target for this disease.

@ast

ERBB receptor signaling promot ...... eutic target for this disease.

@en

ERBB receptor signaling promot ...... eutic target for this disease.

@nl

type

label

ERBB receptor signaling promot ...... eutic target for this disease.

@ast

ERBB receptor signaling promot ...... eutic target for this disease.

@en

ERBB receptor signaling promot ...... eutic target for this disease.

@nl

prefLabel

ERBB receptor signaling promot ...... eutic target for this disease.

@ast

ERBB receptor signaling promot ...... eutic target for this disease.

@en

ERBB receptor signaling promot ...... eutic target for this disease.

@nl

P1433

Q34153957-50740E3B-E647-4851-A1BF-6CD2D4DC9827

P1476

Q34153957-F5551E3B-68C0-4D37-AF9F-0B0FC397FD5C

P2093

Q34153957-0A751B70-C152-4B1B-9F72-7BACA66474AA

Q34153957-1A7C3C41-A9A6-46FB-AACF-CC9028B542DF

Q34153957-2223CD69-E3BE-4238-8F35-2E8063EA9B3C

Q34153957-30D559E6-A9A7-4EA7-B124-1C735149822E

Q34153957-3E65E0B0-F2E6-4F29-857B-4DF57D057E07

Q34153957-4850CCA0-9293-49C1-8A32-D55F2F83F159

Q34153957-4E79EAC4-9458-40CB-BDD8-CE0F53F23293

Q34153957-BED4AB17-C150-4157-BBD1-6CC040694BB6

Q34153957-C2BE89A2-D258-4F1A-91C1-1D53B9BFC6BD

Q34153957-F6F7D836-D5FC-4E0E-A5CE-1FBCEC4BEDF2

P304

Q34153957-03D6EDE8-B549-42BC-802A-8B951C825B48

P31

Q34153957-5A898AF4-582B-4DE0-A16E-F3771536EB53

P407

Q34153957-3D48CAC1-7B78-442D-ADC8-3CB3AA360CD3

P433

Q34153957-E637D11E-24C1-4A3E-AE77-31119069C815

P478

Q34153957-84736DD9-2330-4344-AED3-F453CA6E301E

P50

Q34153957-7E17C28E-FBFF-430B-87AF-571A2BFCAF23

P577

Q34153957-423F961B-E581-4006-9214-9366D3401512

P698

Q34153957-ED0A4FC4-E1B5-438C-B28D-6CF1262B3DEF

P1433

Clinical Cancer Research

P1476

ERBB receptor signaling promot ...... peutic target for this disease

@en

P2093

Adrian J Frank

http://www.w3.org/2001/XMLSchema#string

Cynthia Wetmore

http://www.w3.org/2001/XMLSchema#string

David W Ellison

http://www.w3.org/2001/XMLSchema#string

Hannu Haapasalo

http://www.w3.org/2001/XMLSchema#string

Lyndsay Bentley

http://www.w3.org/2001/XMLSchema#string

Michele Connelly

http://www.w3.org/2001/XMLSchema#string

Richard J Gilbertson

http://www.w3.org/2001/XMLSchema#string

Roberto Hernan

http://www.w3.org/2001/XMLSchema#string

Teemu T Junttila

http://www.w3.org/2001/XMLSchema#string

Tom Curran

http://www.w3.org/2001/XMLSchema#string

P304

3054-3064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12374672

http://www.w3.org/2001/XMLSchema#string